AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada’s Approval for the Treatment of Psoriatic Arthritis

 AbbVie’s Rinvoq (upadacitinib) Receives the Health Canada’s Approval for the Treatment of Psoriatic Arthritis

Shots:

  • The approval is based on data from two P-III studies i.e SELECT-PsA 1 & 2 evaluating the safety & efficacy of Rinvoq vs PBO in 2,000+ patients with active PsA who have had an inadequate response to methotrexate or other DMARDs
  • The studies met their 1EPs of ACR20 response @12wks., Rinvoq (15mg) showed non-inferiority to adalimumab for ACR20 response, improvements in HAQ-DI & skin symptoms (PASI 75), a greater proportion of patients achieved minimal disease activity
  • The safety profile was consistent with previously reported data in RA with no new safety risks observed. Rinvoq is a selective & reversible JAK inhibitor that interferes with the JAK-STAT signaling pathway

Click here to­ read full press release/ article | Ref: AbbVie | Image: AbbVie

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post